Thanks! You've successfully subscribed to the BONEZONE®/OMTEC® Monthly eNewsletter!

Please take a moment to tell us more about yourself and help us keep unwanted emails out of your inbox.

Choose one or more mailing lists:
BONEZONE/OMTEC Monthly eNewsletter
OMTEC Conference Updates
Advertising/Sponsorship Opportunities
Exhibiting Opportunities
* Indicates a required field.

Company Financials: Orthopaedics and Spine

Exhibit 1 displays companies’ orthopaedic sales growth for 2013 vs. 2012, as reported to date. Performance highlights follow, and pertain to both 4Q13 and 2013 overall, as noted.

Exhibit 1: Orthopaedic Sales¹ Growth by Product Segment: 2013 vs. 2012

Financial-Table.3.14 no-notes

Notes to Exhibit I
1Orthopaedic products except as indicated; constant currency, pro forma growth
2For the quarter ended 11/30/13. Includes Dental. Spine includes Bone Stim and Biologics; Bone Stim reflects all Bone
  Healing sales.
3For the period ended 12/31/13
4Extremities: extremities + fixation combined; Endoscopy: endoscopic + communications, most of which is orthopaedic;
  Spine: neuro + spine. Total growth excludes Patient Handling.
5ORTHOWORLD estimates

(for fiscal 2Q14, ended 11/30/13)
$825.7MM, +5% (U.S. $493.1MM, +5%; Europe $211.8MM, +6%; International $120.8MM, +7%)
• Hips $167.7MM, +4% (U.S. +3%)
• Knees $264.0MM, +8% (U.S. +8%)
• Sports Med/Extremities/Trauma (S.E.T.) $160.3MM, +6% (U.S. +6%)
• Spine, Bone Healing & Microfixation $104.9MM, +2% (U.S. -2%)
• Dental $70.5MM, +5% (U.S. +10%)
• Cement, Biologics & Other $58.3MM, +3% (U.S. -2%)

- Overall growth attributed to improvement in Europe, combination of improving market conditions, share gains, large distributor orders
- Specifically, Spain market showing significant gains across all segments
- Based on customer/distributor conversations, market stable during quarter, U.S. volumes appear to be increasing

- Worldwide hip/knee pricing decreased at low single-digit rate
- Strong demand for Taperloc Complete and Echo lines, Arcos femoral revision system
- Launched G7 multi-bearing acetabular system in U.S. and Japan, rollout will continue into FY15
- G7’s implant/instrument color coding system is designed to simplify procedures in the OR; when used with Orthosize 2D or Signature 3D pre-op planning, can help reduce the need for a large number of instruments/trays

- Claims #1-#2 position in U.S. revision knees
- Confirmed AAOS debut of XP bi-cruciate preserving arthroplasty device, launch slated for 2H14

- Growth primarily from extremities, such as Comprehensive Shoulder, ExploR Modular Radial Head; segment in 24th consecutive quarter of double-digit increases
- Launched ToggleLoc with ZipLoop line extension, with retrograde zipping and revision implant
- Launching Signature Personalized Patient Care Guide System in FY3Q, to support intra-op positioning of glenoid components
- Commenced global launch of DVR Crosslock ePAK distal radius plate system: pre-sterilized disposable kit comprising implant + instruments; has now been used in Australia, Europe, Latin America, South America, U.S.
- Initiated U.S. launch of OsseoTi porous metal osteotomy wedges as an alternative to allograft wedges for foot/ankle

Spine, Bone Healing & Microfixation
- Closed Lanx aquisition
- Strong adoption of Lineum and MaxAn cervical products supported growth, as did Cellentra stem cell product and sales of the acquired Timberline Lateral System
- Received approval to enroll 50 patients in IDE study of SpinalPak stimulator for early treatment of degenerative disc disease

Cement, Biologics & Other
- Continued strong Japan market acceptance for Cobalt bone cement
- Investments in biologic programs includes NStride APS autologous therapy for early-stage OA, a potential substitute for hyaluronic acid; U.S. pilot study to commence in 2H14